Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study

Autor Joshi, Amit, Kate, Shruti, Noronha, Vanita, Patil, Vijay, Trivedi, Vaishakhi, Goud, Supriya, More, Sucheta, Bhairva, Sandeep, Prabhash, Kumar
Vydáno v Ecancermedicalscience (2018)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell l...

Autor Patil, Vijay, Joshi, Amit, Noronha, Vanita, Agarwala, Vivek, Chougule, Anuradha, Kanan, Sadhana, Bhattacharjee, Atanu, Chandrasekharan, Arun, Pande, Nikhil, Simha, Vijai, Goud, Supriya, More, Sucheta, Kumar, Rajiv, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Vydáno v Oncotarget (2019)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Autor Noronha, Vanita, Patil, Vijay, Joshi, Amit, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, More, Sucheta, Goud, Supriya, Karpe, Ashay, Ramaswamy, Anant, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Vydáno v Ecancermedicalscience (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Autor Joshi, Amit, Patil, Vijay, Noronha, Vanita, Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Vydáno v Lung India (2018)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Autor Joshi, Amit, Noronha, Vanita, Patil, Vijay M., Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Vydáno v Chemother Res Pract (2017)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

Autor Patil, Vijay Maruti, Noronha, Vanita, Joshi, Amit, Choughule, Anuradha Bharat, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Vydáno v ESMO Open (2017)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

Autor Patil, Vijay, Noronha, Vanita, Joshi, Amit, Chougule, Anuradha, Kannan, Sadhana, Bhattacharjee, Atanu, Goud, Supriya, More, Sucheta, Chandrasekharan, Arun, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Dsouza, Hollis, Majumdar, Swaratika, Das, Sudeep, Zawar, Abhinav, Khaddar, Satvik, Kumar, Amit, Singh, Gunjesh, Kumar, Kanteti Aditya Pavan, Ravind, Rahul, Trivedi, Vaishakhi, Behel, Vichitra, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Vydáno v EClinicalMedicine (2019)